Tuesday, October 08, 2024
Cell and gene therapy consulting firm Dark Horse Consulting Group has acquired BioTechLogic.
Tuesday, October 15, 2024
MeiraGTx revealed positive top-line data from a clinical study of its investigational gene therapy for the treatment of Parkinson’s disease, positioning the company for a phase 3 trial.
Tuesday, October 15, 2024
uniQure has dosed the first patient in the phase 1/2 clinical trial of its experimental gene therapy, AMT-162, for the treatment of SOD1-ALS.
Tuesday, October 15, 2024
Tolerance Bio, a new cell therapy biotech, has emerged from stealth mode with $17.2 million in funding.
Wednesday, October 16, 2024
Mongoose Bio has signed a strategic partnership with viral vector CDMO Matica Biotechnology focused on the development and production of lentivirus for Mongoose’s TCR-T pipeline for cancer treatment.
Thursday, October 17, 2024
OmniaBio's new CDMO site will add state-of-the-art CGT capacity and employ AI and automation to achieve critical product supply efficiencies for clients.
Tuesday, October 22, 2024
New York governor Kathy Hochul unveiled plans for New York BioGenesis Park, a cell and gene therapy innovation hub in Nassau County, Long Island.
Tuesday, October 22, 2024
The U.S. FDA has provided a clear regulatory pathway to accelerated approval for Sangamo Therapeutics’ gene therapy product candidate for the treatment of Fabry disease.
Thursday, October 24, 2024
Intellia Therapeutics’ phase 2 data indicates that its CRISPR-based gene editing therapy has the potential to become the first functional cure for hereditary angioedema.
Thursday, October 24, 2024
In a deal that could exceed $1 billion, Roche’s bets on Dyno’s platform and sequence design technologies enabling in vivo gene delivery.